TXNL1 induces apoptosis in cisplatin resistant human gastric cancer cell lines

Current Cancer Drug Targets

Volumn 14, Issue 9, 2014, Pages 850-859

  Ni, Pan ^a   Xu, Wenxia ^a,b   Zhang, Yajie ^a   Chen, Qi ^a   Li, Aiping ^a   Wang, Shouyu ^a   Xu, Shan ^a   Zhou, Jianwei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2; Cisplatin; Gastric cancer; TXNL1; XRCC1

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BCL 2; SMALL INTERFERING RNA; THIOREDOXIN; THIOREDOXIN LIKE PROTEIN 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, HUMAN; BIOLOGICAL MARKER; DNA BINDING PROTEIN; HYBRID PROTEIN; TUMOR PROTEIN; TXNL1 PROTEIN, HUMAN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; NICK END LABELING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION; WESTERN BLOTTING; AGONISTS; ANTAGONISTS AND INHIBITORS; CFU COUNTING; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MITOCHONDRION; OSMOLARITY; PATHOLOGY; RNA INTERFERENCE; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; CISPLATIN; COLONY-FORMING UNITS ASSAY; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOCHONDRIA; NEOPLASM PROTEINS; OSMOLAR CONCENTRATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; THIOREDOXINS;

EID: 84921914426     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666141028094612     Document Type: Article

References (28)

1. Chen, X.L.; Chen, X.Z.; Yang, C.; Liao, Y.B.; Li, H.; Wang, L.; Yang, K.; Li, K.; Hu, J.K.; Zhang, B.; Chen, Z.X.; Chen, J.P.; Zhou, Z. G. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One, 2013, 8, e60320.
2. Rabik, C.A.; Dolan, M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev., 2007, 33, 9-23.
3. Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31, 1869-1883.
4. Kartalou, M.; Essigmann, J.M. Recognition of cisplatin adducts by cellular proteins. Mutat. Res., 2001, 478, 1-21.
5. Myint, W.K.; Ng, C.; Raaphorst, G.P. Examining the nonhomologous repair process following cisplatin and radiation treatments. Int. J. Radiat. Biol., 2002, 78, 417-424.
6. Jin, J.; Chen, X.; Zhou, Y.; Bartlam, M.; Guo, Q.; Liu, Y.; Sun, Y.; Gao, Y.; Ye, S.; Li, G.; Rao, Z.; Qiang, B.; Yuan, J. Crystal structure of the catalytic domain of a human thioredoxin-like protein. Eur. J. Biochem., 2002, 269, 2060-2068.
7. Goroncy, A.K.; Koshiba, S.; Tochio, N.; Tomizawa, T.; Inoue, M.; Tanaka, A.; Sugano, S.; Kigawa, T.; Yokoyama, S. Solution structure of the C-terminal DUF1000 domain of the human thioredoxin-like 1 protein. Proteins, 2010, 78, 2176-2180.
8. Andersen, K.M.; Madsen, L.; Prag, S.; Johnsen, A.H.; Semple, C.A.; Hendil, K.B.; Hartmann-Petersen, R. Thioredoxin Txnl1/ TRP32 is a redox-active cofactor of the 26 S proteasome. J. Biol. Chem., 2009, 284, 15246-15254.
9. Wiseman, R.L.; Chin, K.T.; Haynes, C.M.; Stanhill, A.; Xu, C.F.; Roguev, A.; Krogan, N.J.; Neubert, T.A.; Ron, D. Thioredoxinrelated Protein 32 is an arsenite-regulated Thiol Reductase of the proteasome 19 S particle. J. Biol. Chem., 2009, 284, 15233-15245.
10. Jimenez, A.; Pelto-Huikko, M.; Gustafsson, J.A.; Miranda-Vizuete, A. Characterization of human thioredoxin-like-1: potential involvement in the cellular response against glucose deprivation. FEBS Lett., 2006, 580, 960-967.
11. Ishii, T.; Funato, Y.; Miki, H. Thioredoxin-related protein 32 (TRP32) specifically reduces oxidized phosphatase of regenerating liver (PRL). J. Biol. Chem., 2013, 288, 7263-7270.
12. Gong, F.; Peng, X.; Sang, Y.; Qiu, M.; Luo, C.; He, Z.; Zhao, X.; Tong, A. Dichloroacetate induces protective autophagy in LoVo cells: involvement of cathepsin D/thioredoxin-like protein 1 and Akt-mTOR-mediated signaling. Cell Death Dis., 2013, 4, e913.
13. Wang, S.; Wu, X.; Chen, Y.; Zhang, J.; Ding, J.; Zhou, Y.; He, S.; Tan, Y.; Qiang, F.; Bai, J.; Zeng, J.; Gong, Z.; Li, A.; Li, G.; Roe, O. D.; Zhou, J. Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clin. Cancer Res., 2012, 18, 2987-2996.
14. Xu, W.; Wang, S.; Chen, Q.; Zhang, Y.; Ni, P.; Wu, X.; Zhang, J.; Qiang, F.; Li, A.; Roe, O. D.; Xu, S.; Wang, M.; Zhang, R.; Zhou, J. TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer. Cell Death Dis., 2014, 5, e1055.
15. Zhou, J.; Ye, J.; Zhao, X.; Li, A.; Zhou, J. JWA is required for arsenic trioxide induced apoptosis in HeLa and MCF-7 cells via reactive oxygen species and mitochondria linked signal pathway. Toxicol. Appl. Pharmacol., 2008, 230, 33-40.
16. Huang, S.; Chen, M.; Shen, Y.; Shen, W.; Guo, H.; Gao, Q.; Zou, X. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett., 2012, 315, 198-205.
17. Fichtinger-Schepman, A.M.; van der Veer, J.L.; den Hartog, J.H.; Lohman, P.H.; Reedijk, J. Adducts of the antitumor drug cisdiamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry, 1985, 24, 707-713.
18. Fichtinger-Schepman, A.M.; van Oosterom, A.T.; Lohman, P.H.; Berends, F. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res., 1987, 47, 3000-3004.
19. Damia, G.; Imperatori, L.; Stefanini, M.; D'Incalci, M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int. J. Cancer, 1996, 66, 779-783.
20. Aloyz, R.; Xu, Z.Y.; Bello, V.; Bergeron, J.; Han, F.Y.; Yan, Y.; Malapetsa, A.; Alaoui-Jamali, M.A.; Duncan, A.M.; Panasci, L. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res., 2002, 62, 5457-5462.
21. Boeckman, H.J.; Trego, K.S.; Turchi, J.J. Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol. Cancer Res., 2005, 3, 277-285.
22. Basu, A.; Krishnamurthy, S. Cellular responses to Cisplatininduced DNA damage. J. Nucleic Acids, 2010, 2010.
23. Li, B.; Wang, L.; Chi, B. Upregulation of periostin prevents P53-mediated apoptosis in SGC-7901 gastric cancer cells. Mol. Biol. Rep., 2013, 40, 1677-1683.
24. Arner, E.S.; Holmgren, A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem., 2000, 267, 6102-6109.
25. Gromer, S.; Urig, S.; Becker, K. The thioredoxin system--from science to clinic. Med. Res. Rev., 2004, 24, 40-89.
26. Hanschmann, E.M.; Godoy, J.R.; Berndt, C.; Hudemann, C.; Lillig, C.H. Thioredoxins, glutaredoxins, and peroxiredoxins-molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling. Antioxid. Redox Signal., 2013.
27. Wangpaichitr, M.; Wu, C.; You, M.; Maher, J.C.; Dinh, V.; Feun, L.G.; Savaraj, N. N',N'-Dimethyl-N',N'-bis(phenylcarbonothioyl) propanedihydrazide (Elesclomol) selectively kills cisplatin resistant lung cancer cells through reactive oxygen species (ROS). Cancers (Basel),. 2009, 1, 23-38.
28. Wangpaichitr, M.; Sullivan, E.J.; Theodoropoulos, G.; Wu, C.; You, M.; Feun, L.G.; Lampidis, T.J.; Kuo, M.T.; Savaraj, N. The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Mol. Cancer Ther., 2012, 11, 604-615.